Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 2c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.41), $0.02 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $20 thousand versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• FirstCash to acquire UK pawn operator Ramsdens for £206 million
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform